Published in BMJ on March 27, 2012
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015) | NCT00092534
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
Discussing the diagnosis of HPV-OSCC: common questions and answers. Oral Oncol (2013) 1.09
Anal cancer treatment: current status and future perspectives. World J Gastroenterol (2015) 0.97
Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis (2013) 0.97
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
HPV prophylactic vaccination in males improves the clearance of semen infection. EBioMedicine (2015) 0.86
The time has come to make cervical cancer prevention an essential part of comprehensive sexual and reproductive health services for HIV-positive women in low-income countries. J Int AIDS Soc (2015) 0.84
Should male circumcision be advocated for genital cancer prevention? Asian Pac J Cancer Prev (2012) 0.84
Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. PLoS One (2014) 0.84
Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men. Clin Infect Dis (2015) 0.82
Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Eur Arch Otorhinolaryngol (2013) 0.81
Human papillomavirus vaccination: current indications and future directions. Obstet Gynecol Clin North Am (2013) 0.81
The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol (2014) 0.80
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study. Wien Klin Wochenschr (2013) 0.80
Answering human papillomavirus vaccine concerns; a matter of science and time. Infect Agent Cancer (2013) 0.79
Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol (2016) 0.78
Early infant male circumcision: Systematic review, risk-benefit analysis, and progress in policy. World J Clin Pediatr (2017) 0.77
The role of Human Papilloma Virus (HPV) vaccination in the prevention of anal cancer in individuals with Human Immunodeficiency Virus-1 (HIV-1) infection. Ther Adv Vaccines (2013) 0.77
VIN usual type-from the past to the future. Ecancermedicalscience (2015) 0.77
Laser capture microdissection as a tool to evaluate human papillomavirus genotyping and methylation as biomarkers of persistence and progression of anal lesions. BMJ Open (2015) 0.76
Effect of quadrivalent HPV vaccination on HPV related disease in women treated for cervical or vulvar/vaginal disease. BMJ (2012) 0.75
Sexual and reproductive health and human rights of women living with HIV. J Int AIDS Soc (2015) 0.75
"Saving lives": Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria. Soc Sci Med (2016) 0.75
Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials. Basic Clin Androl (2016) 0.75
Is administration of the HPV vaccine during pregnancy feasible in the future? Expert Rev Vaccines (2013) 0.75
What do women with gynecologic cancer know about HPV and their individual disease? A pilot study. BMC Cancer (2014) 0.75
Reduction in subsequent HPV related disease was unrelated to vaccination. BMJ (2012) 0.75
American academy of dermatology. P T (2015) 0.75
Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PLoS One (2014) 0.75
[Researcher of the month, October 2012]. Wien Klin Wochenschr (2012) 0.75
Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness. Cancer (2017) 0.75
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol (2008) 6.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.40
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis (2007) 2.17
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis (2002) 2.05
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer (2011) 1.96
The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol (2006) 1.91
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis (2007) 1.90
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine (2010) 1.65
Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. Am J Epidemiol (2008) 1.62
An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS (1998) 1.57
Therapy for genital human papillomavirus-related disease. J Clin Virol (2005) 1.45
The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS (1996) 1.42
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Management of genital warts. Am Fam Physician (2004) 1.24
Post-licensure monitoring of HPV vaccine in the United States. Vaccine (2010) 1.24
Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev (2009) 1.15
The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS (2004) 1.14
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer (2011) 1.12
The Bethesda System 2001: an update of new terminology for gynecologic cytology. Clin Lab Med (2003) 1.06
The 2001 ASCCP management guidelines for cervical cytology. Am Fam Physician (2004) 0.81
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol (2010) 9.86
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol (2012) 6.05
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96
Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: a series of 50 cases from a tertiary teaching hospital. Acta Obstet Gynecol Scand (2012) 5.93
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res (2012) 3.82
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine (2012) 3.03
Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis (2005) 3.00
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis (2012) 2.51
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Early acquisition of anogenital human papillomavirus among teenage men who have sex with men. J Infect Dis (2013) 2.40
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecol Oncol (2013) 2.01
Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer (2009) 1.98
Azithromycin failure in Mycoplasma genitalium urethritis. Emerg Infect Dis (2006) 1.98
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer (2006) 1.92
Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect (2011) 1.78
Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol (2006) 1.78
Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J (2007) 1.77
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol (2006) 1.77
Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol (2009) 1.77
Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev (2011) 1.74